Trial Profile
An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Iscalimab (Primary)
- Indications Graves' disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 12 Sep 2019 Results published in the Journal of Clinical Endocrinology and Metabolism
- 01 Jun 2017 Status changed from recruiting to completed.
- 14 Mar 2017 Planned End Date changed from 1 Apr 2017 to 2 May 2017.